For fifty years, the biopharmaceutical industry has been losing a quiet war against its own productivity.
Since 1950, R&D output has halved roughly every nine years — a trend so persistent and so counterintuitive that economist Jack Scannell named it Eroom's Law (Moore's Law, spelled backwards). While technology, genomics, computational power, and scientific understanding have all advanced dramatically, the number of new drugs approved per billion dollars spent has fallen eighty-fold. Drug development costs have risen from $180 million in 1970 to more than $2.6 billion today.
The conventional explanation focuses on the science: harder targets, higher regulatory bars, more complex diseases. And those factors are real. But they are not the whole story.
The culprit isn't the science. It's the friction around the science.
And that friction has a name: the Discovery Tax.
Biopharma has been losing productivity for 50 years — and the real culprit isn't the science. It's the operational friction surrounding it.The Discovery Tax is the quantifiable cost of operational friction in scientific outsourcing: the accumulated time, money, and momentum lost every year to the administrative, logistical, and procurement burden that sits between a scientist's idea and its execution.
It is not the cost of difficult science. It is the cost of everything that gets in the way of science.
The Discovery Tax does not concentrate in one place. It distributes itself across every handoff point in the external R&D lifecycle, accumulating invisibly in the white space between systems, teams, and processes that were never designed to work together.
Supplier Sourcing & Vetting (40–60 hours/year per scientist): Without access to a curated, intelligence-enriched supplier management network, researchers spend disproportionate time simply finding the right external partner — relying on personal networks, fragmented databases, and institutional memory. Every search starts from scratch. Every vetting exercise repeats work that has already been done somewhere else in the organization.
Legal & Contracting (80–120 hours/year per scientist): This is the single largest friction point, and the most structurally embedded. MSAs, SOWs, budget approvals — each requires coordinated action across stakeholders who have different priorities and different timelines. Without pre-established master agreements and intelligent contract management, every new engagement reopens the same negotiation.
Procurement Onboarding (20–30 hours/year per scientist): Generic ERP systems were not built for the velocity and specificity of scientific outsourcing. Every new supplier, every new project, every new engagement requires manual configuration and onboarding that bypasses the intelligence scientists actually need.
Administrative Coordination (40–60 hours/year per scientist): Tracking project status, managing invoices, reconciling spend data, coordinating across partners — in the absence of a single source of truth, this work falls to the scientists themselves, consuming research bandwidth that cannot be recovered.
Each of these friction points looks, in isolation, like business as usual. Collectively, they constitute a structural tax on the organization's ability to do science.
The average scientist loses approximately 5 weeks per year (roughly 180 to 270 hours) to procurement friction alone. That is not an estimate derived from surveys of general dissatisfaction. It is the sum of four specific, documented friction points that occur in virtually every external R&D engagement.
| Friction Point | Annual Time Lost Per Preclinical Scientist |
|---|---|
| Supplier sourcing & vetting | 40–60 hours |
| Legal & contracting | 80–120 hours |
| Procurement onboarding | 20–30 hours |
| Administrative coordination | 40–60 hours |
| Total | ~180–270 hours (~5 weeks) |
At a fully loaded scientist cost of approximately $150,000 per year — roughly $75 per hour, five weeks of lost time translates to $15,000 per scientist per year in direct productivity loss. And that figure accounts only for time. It does not include the opportunity cost of delayed timelines, slower time-to-market, or the compounding effect of programs that slip by weeks while waiting for a contract to clear legal review.
Scale that across an organization, and the Discovery Tax becomes one of the largest unreported line items in R&D operations:
| R&D Team Size | Annual Discovery Tax |
|---|---|
| 25 scientists | $375,000 |
| 50 scientists | $750,000 |
| 100 scientists | $1,500,000 |
| 250 scientists | $3,750,000 |
| 500 scientists | $7,500,000 |
These are not hypothetical projections. They are the direct, arithmetic consequence of 5 weeks of friction per scientist, applied across organizations that are already under enormous pressure to do more science, faster, with tighter budgets.
For a mid-sized biopharma running a research organization of 250 scientists, the Discovery Tax is a $3.75 million annual drain — before a single opportunity cost is counted.
Once you calculate it, the number is impossible to ignore.
The Discovery Tax costs a 250-person R&D organization $3.75 million a year — and it doesn't appear anywhere in the budget.Here is the strategic frame that elevates the Discovery Tax beyond an operational efficiency conversation.
Eroom's Law has persisted for fifty years not because the industry lacks scientific ambition or technological capability. It has persisted, in significant part, because the infrastructure around science has not kept pace with science itself. The systems, processes, and tools through which biopharma organizations access external R&D capability were built for a different era — one of lower complexity, slower timelines, and less strategic dependence on external partners.
Today, external R&D is not a procurement category. It is a core strategic capability. The organizations that can access the right partner, at the right time, with zero friction are the organizations that move fastest — and in drug development, speed is directly correlated with value.
Eliminating the Discovery Tax is not a productivity improvement. It is a structural intervention in a fifty-year trend. That is not hyperbole. It is the logical consequence of removing the primary non-scientific constraint on R&D output.
The organizations that address it first will not just run more efficient operations — they will run faster science. And in an industry where time-to-market is measured in years and the cost of delay is measured in billions, that advantage compounds. Explore how digital procurement is becoming a strategic lever for faster, smarter drug development.
The reason the Discovery Tax has persisted is the same reason many structural inefficiencies persist: it has never been named, measured, or held accountable. Friction is everyone's problem, so it is no one's problem. It accumulates in the background while leadership attention focuses on the science.
Naming it changes that dynamic.
When you put a number to the Discovery Tax — $3.75 million annually for an organization of 250 researchers — it stops being a background condition and starts being a decision. At that point, the question is no longer whether to address it. The question is why it has not been addressed already.
Biopharma executives and R&D procurement leaders who are serious about reversing the productivity trend (not just optimizing the margins) are beginning to recognize that the path to faster discovery runs directly through eliminating the tax on that discovery.
The Discovery Tax is not inevitable. It is a structural problem, and structural problems have structural solutions.
In the posts ahead in this series, we'll go deeper: quantifying the full opportunity cost of delayed timelines, examining how the Discovery Tax manifests differently across organizational types, and exploring what it means for the industry's most persistent productivity challenge.
What is the Discovery Tax costing your organization — and does it appear anywhere in your R&D budget?
Next in the series: Eroom's Law Culprit — Why the friction around science, not the science itself, is the industry's most solvable problem.